Dendritic Cell Cancer Vaccines Market Size, Growth, Trends | Report 2022-2030
The global dendritic cell cancer vaccines market was surpassed at USD 2.23 billion in 2021 and is expected to hit around USD 5.17 billion by 2030, growing at a CAGR of 9.8% from 2022 to 2030.
Dendritic cells(DCs) are a distinct type of immune cell found in the mammalian immune system. These cells induce antigen-specific T cell response and play an important role in anti-tumor activity. Several strategies are being developed to progress dendritic cell cancer vaccines for immunotherapy to promote prolonged life for patients with minimal side effects. For instance, many studies are being conducted to explore the dendritic cell-based vaccination for treating hematological malignancies such as myelodysplastic syndromes, acute myeloid leukemia, and other nonleukemia malignancies.
The treatments such as chemotherapy, radiotherapy, and surgery are standard treatments for carcinoma. These treatments have adverse and prolonged effects such as damage to the lungs, kidneys, heart, and reproductive organs, memory loss, poor brain function, and stroke-like symptoms. The effects can be delayed in a few cases; tumors may show up a second time after a few years. Immunotherapy treatment can induce the immune system to attack tumor-causing cells with high accuracy and specificity. For instance, a study conducted by NCBI in 2021 using dendritic cell-based immunotherapy in patients resulted in a strengthened immune response, no specific side effects, and prolonged survival time. Such of these vaccines over standard treatment options are expected to drive the market in near future.
The growing prevalence of cancer cases is anticipated to increase the adoption of dendritic cell vaccines in the coming years. According to WHO, cancer is a foremost cause of deaths, globally approximately, 10 million deaths were accounted in 2020. In addition, according to CDC in the U.S., 1,752,735 new cancer cases and 599,589 deaths were recorded in 2019. Furthermore, the increasing consumption of adulterated food, rising incidences of smoking & drinking, and lifestyle choices such as food, stress and physical inactivity are key factors causing cancer globally.
Moreover, increasing research & development and funding to develop dendritic cell cancer vaccine based immunotherapy treatments is anticipated to boost the market growth during the forecast period. For instance, in December 2021, PDC*line Pharma received funding of USD 20m to support clinical trial to develop dendritic cell cancer vaccine for bronchogenic carcinoma. Furthermore, according to an article published on newswise in December 2021, Moffitt Cancer Center researchers are developing dendritic cell vaccine targeting HER3, a protein involved in for causing and spreading different types of cancers.
The market is segmented by product, end-user, and region. The product segment includes CeraVax, Sipuleucel-T and others. The end-user segment includes pediatrics and adults.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 2.23 billion |
| Revenue Forecast by 2030 | USD 5.17 billion |
| Growth rate from 2022 to 2030 | CAGR of 9.8% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Product, End-user, Region |
| Companies Covered |
3M company, GlaxoSmithKline plc, Activartis, Batavia Bioservices, Argos Therapeutics, Sanpower Corporation, Elios Therapeutics, DanDrit Biotech, DCPrime, ImmunoCellular Therapeutics |
Key Players
Market Segmentation
By Product
By End-user
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dendritic Cell Cancer Vaccines Market
5.1. COVID-19 Landscape: Dendritic Cell Cancer Vaccines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dendritic Cell Cancer Vaccines Market, By Product
8.1. Dendritic Cell Cancer Vaccines Market, by Product, 2022-2030
8.1.1. CreaVax
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Sipuleucel-T (Provenge)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Other
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Dendritic Cell Cancer Vaccines Market, By End-user
9.1. Dendritic Cell Cancer Vaccines Market, by End-user, 2022-2030
9.1.1. Pediatrics
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Adults
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Dendritic Cell Cancer Vaccines Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by End-user (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 11. Company Profiles
11.1. 3M company
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. GlaxoSmithKline plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Activartis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Batavia Bioservices
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Argos Therapeutics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Sanpower Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Elios Therapeutics
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. DanDrit Biotech
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. DCPrime
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. ImmunoCellular Therapeutics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers